SNBL USA Names New Director of Safety Pharmacology

Everett, WA – December 12, 2008 - SNBL USA is excited to announce Frederick Sannajust, PharmD, PhD, Prof. has recently joined the SNBL USA management team and has been appointed Director of Safety Pharmacology.

Prior to joining SNBL USA, Dr. Sannajust held many positions including: Professor of Neuropharmacology at the Faculty of Pharmacy, University of Tours/France; Director for the Institute of Cardiovascular and Neuropharmacology Research (IRNC); Head of Safety Pharmacology Department at Huntington Life Sciences; and West Coast Head of Cardiovascular De-risking and Safety Pharmacology at Johnson & Johnson Co.

Dr. Sannajust brings SNBL USA a unique combination of expertise in preclinical Safety Pharmacology, preclinical Research & Development for NCEs and biologics, and early preclinical Discovery Research (Cardiovascular, CNS, Respiratory, Oncology, Ocular pharmacology, etc.). He will lead the global strategy and manage daily operations of the SNBL USA Safety Pharmacology department and his extensive experience in rat/rabbit/dog/ nonhuman primates (NHPs) Cardiovascular and CNS telemetry research and 18+ years of experience in in-vitro/ex-vivo/in-vivo Pharmacology will prove to be invaluable as we continue to expand our services to better serve our clients and provide the most comprehensive contract pharmacology services in the industry.

About SNBL USA's Safety Pharmacology Program

In line with International Conference on Harmonisation (ICH) guidelines for Safety Pharmacology testing, SNBL USA offers an in vivo core battery of studies (CV, CNS and Respiratory). Our safety pharmacology program provides a wide range of comprehensive and integrated in vivo evaluations designed to meet the requirements for the testing of pharmaceutical compounds (eg, small molecules, biologics, vaccines, mAbs, gene therapies, etc.).

SNBL USA maintains dedicated suites for NHP telemetry studies, allowing for a variety of study designs and group configurations. We have the capability to measure the effects of NCEs and biologics on cardiovascular (eg, blood pressure, heart rate, ECGs, LVP) and respiratory parameters in telemetered NHPs. Our GLP-compliant telemetry data acquisition program is flexible and can be configured for either continuous (up to 30 hours) or intermittent (using scheduled recording) data collection. In addition, our data acquisition system includes synchronized video and physiological data capture with remote monitoring capabilities. We utilize a modified Irwin test or Functional Observation Battery (FOB) to detect putative CNS side effects in rodents and NHPs (eg, motor activity, behavior, coordination, sensory/motor reflex responses and body temperatures).

Contact us today for any questions regarding SNBL USA’s Safety Pharmacology services. You may reach the Client Services team via info@snblusa.com or +1 (425) 322-1950.

About SNBL USA, Ltd.

Headquartered in Everett, WA, SNBL USA, Ltd. is a preclinical CRO that specializes in nonhuman primate (NHP) and small animal research. Study programs range from regulatory toxicology to customized study designs and disease models. Specialized programs include reproductive toxicology, safety pharmacology, immunotoxicology and carcinogenicity. SNBL USA’s Laboratory Services division intelligently applies extensive experience, comprehensive scientific capabilities, and modern technology to bring outstanding support to all client research. Through a commitment to investment and excellence, SNBL USA strives to offer the biotechnology and pharmaceutical industries unparalleled quality in both science and service. For additional information call 425.407.0121 or visit www.snblusa.com.